Aether Industries enters its Q4 earnings print riding strong momentum in its contract manufacturing and large-scale manufacturing segments. Investors will be looking for updates on the commissioning status of Site-5 production blocks and the sustainability of margins as the company navigates a shifting end-user mix away from pharma.
| Results date | May 15, 2026 |
|---|---|
| Quarter | Q4 |
| Previous quarter revenue | Rs. 3,171 million |
| Previous quarter PAT | Rs. 645 million |
| Previous quarter EBITDA margin | 34.1% |
| Market cap | Rs. 14665.8 Cr |
| CMP | Rs. 1105.35 |
The board meeting is scheduled for May 15, 2026, to consider and approve the audited financial results for the Q4 and FY ended March 31, 2026.
In its most recently reported quarter, Aether Industries posted revenue of Rs. 3,171 million, PAT of Rs. 645 million, and an EBITDA margin of 34.1%. Operating performance is currently supported by the ramp-up of Site-3++ which commenced commercial operations on February 22, 2026, and the continued scaling of the Baker Hughes contract which contributed Rs. 51 crores in Q2 FY26. Management has maintained a long-term growth outlook of approximately 25% and continues to target EBITDA margins in the 29-30% range despite ongoing competitive pricing pressures in the LSM segment due to Chinese dumping. The company expects PAT margins to remain constrained between 19% and 20% throughout the current cycle due to higher depreciation charges from recent capital expenditure and increased finance costs.
Performance vs Guidance Tracking
Site-Specific Operational Status
Risks and Headwinds to Monitor
Aether Industries will announce its Q4 FY 2025-2026 results on May 15, 2026.
Aether Industries reported revenue of Rs. 3,171 million in Q3 FY 2025-2026.
Site-5 is in the first phase of development, with two production blocks expected to be commissioned in Q4 FY26. The total capital expenditure for this site is estimated at Rs. 2,200-2,300 crores extending through FY30.
Management plans to fund future capital expenditure through a mix of internal accruals and debt. There are no plans for further equity fundraising for the next 5 to 7 years.
Yes, the company is ahead of its guidance. It achieved a working capital cycle of 149 days as of September 30, 2025, which is better than the FY26 year-end target of 165-170 days.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now